Advertisement
UK markets close in 5 hours 53 minutes
  • FTSE 100

    8,396.48
    -27.72 (-0.33%)
     
  • FTSE 250

    20,778.28
    -95.05 (-0.46%)
     
  • AIM

    807.40
    -2.54 (-0.31%)
     
  • GBP/EUR

    1.1695
    -0.0003 (-0.02%)
     
  • GBP/USD

    1.2716
    +0.0010 (+0.08%)
     
  • Bitcoin GBP

    55,783.31
    +3,146.53 (+5.98%)
     
  • CMC Crypto 200

    1,526.84
    +38.29 (+2.57%)
     
  • S&P 500

    5,308.13
    +4.86 (+0.09%)
     
  • DOW

    39,806.77
    -196.82 (-0.49%)
     
  • CRUDE OIL

    79.11
    -0.69 (-0.86%)
     
  • GOLD FUTURES

    2,422.10
    -16.40 (-0.67%)
     
  • NIKKEI 225

    38,946.93
    -122.75 (-0.31%)
     
  • HANG SENG

    19,220.62
    -415.60 (-2.12%)
     
  • DAX

    18,684.78
    -84.18 (-0.45%)
     
  • CAC 40

    8,129.70
    -66.26 (-0.81%)
     

Longeveron to Present at the Planet MicroCap Showcase

Longeveron
Longeveron

MIAMI, April 25, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Planet MicroCap Showcase, taking place May 1-2, 2024.

Details for the Company’s presentation:

 

Date:

Wednesday, May 1, 2024

 

Time:

4:30 p.m. PT

 

Webcast:

Click Here

 

 

 

An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.

If you would like to book 1x1 investor meetings with Longeveron Inc. and to attend the Planet MicroCap Showcase: VEGAS 2024, please register here: https://planetmicrocapshowcase.com/signup.

ADVERTISEMENT

1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Investor Contact:

Derek Cole
Investor Relations Advisory Solutions 
derek.cole@iradvisory.com